论文部分内容阅读
目的 研究重组干扰素α 2b(干扰能 )治疗小儿慢性乙型肝炎近期及远期疗效。方法 观察组 31例 ,用干扰能 ,≥ 7岁 30 0万IU ,肌内注射 ,每周 3次 ,<7岁 10 0万IU肌内注射 ,每日 1次 ,连续用 2 7周。对照组 2 6例 ,口服利肝隆 ,疗程亦为 2 7周。结果 疗程结束后 ,观察组丙氨酸转氨酶 (ALT)复常率为 93 5 % ,HBeAg阴转率为 6 4 5 % ,HBV DNA阴转率为 6 1 3% ,HBsAg阴转率为 2 5 8% ,对照组上述指标分别为 30 8%、15 4%、15 4%、0。两组相比有显著差异 ,P <0 0 1。停用干扰能后 12个月 ,按本研究制定的疗效判断标准进行分析 ,观察组显效率、总有效率与对照组相比均有非常显著差异 ,均为P <0 0 1。对部分病例进行 4年的随访 ,观察组疗效优于对照组 ,各项指标相比均有显著差异。结论 干扰能治疗小儿慢性乙型肝炎疗效较理想 ,治疗中未发现严重的副反应 ,随访 4年 ,小儿生长发育未受到影响
Objective To study the short-term and long-term therapeutic effects of recombinant interferon α 2b (interferon) on chronic hepatitis B in children. Methods: The observation group consisted of 31 patients with interictal disturbance, ≥7 years old 30 million IU, intramuscular injection, three times a week, <7 years old 10 million IU intramuscularly, once daily for 27 consecutive weeks. Control group 26 cases, oral Lee liver Long, treatment also for 27 weeks. Results After the course of treatment, the normalization rate of alanine aminotransferase (ALT) in the observation group was 93.5%, the negative conversion rate of HBeAg was 64.5%, the negative conversion rate of HBV DNA was 61.3%, the negative conversion rate of HBsAg was 25 8% in the control group, respectively. The above indexes in the control group were 30.8%, 154%, 154%, 0 respectively. There was a significant difference between the two groups, P <0.01. Twelve months after disabling the disturbance, the curative effect criteria developed in this study were analyzed. There was a significant difference between the observation group and the control group (P <0.01). In some cases of 4-year follow-up, the observation group was better than the control group, the indicators were significantly different. Conclusions Intervention can treat children with chronic hepatitis B more effectively, and no serious side effects are found during the treatment. After 4 years of follow-up, the growth and development of children are not affected